Member Info for KoolKat15

I got laughed at for saying the smart investors cashed out on 10th April particularly by medieval man and Laura. I'm sorry to say, but I told you so. Hopefully traders trying to make a quick buck will learn from this!

Ouch!

UserSteve, you say "That is the concern several users here have - QBT will simply claim that the results are "successful" but give no supporting facts or figures by which the claim be verified". "Just trust us, bruh"

I think you're being unfair here because Lying on a PRN/regulatory announcement is a serious offensive, and it's very, very unlikely this would happen with FG hence, if the results are excellent, this'll be the truth.

Massive opportunity here, price is low, raise out the way, results due by end of April, trip to Vegas.

Yum yum

Hoping this news gives LTH's a spike today. To be fair, it is a very good RNS, and IMO shows Ronjon Nag is taking his time over deployment to ensure everything that goes live meets potential customers expectations.

I also think they'll be available via the Apple App Store soon enough.

Hi UserSteve, why go to Vegas if you don't have anything to showcase?

My feelings based on FG's latest interview and their announcement that test results will be completed by the end of April, is they already know the results are impressive.

I suspect they'll announce excellent results and will be taking these results to Vegas.

Of course, I could be seriously wrong, but investing at £0.0037p, I'm happy to take the risk that some good news will finally arrive.

All IMO - not financial advice DYOR

Phimx, I get everything you're saying particularly regarding a deal/partnership, however, I'm not in this for the medium/longterm. Let's see where the SP is when the test results drop.

Have a good day! Bye for now

Phimx, I was waiting for the raise, as you and others say, investors were warned.

The risk vs reward is obviously still very high here, but with the Placing out the way and as they stated Test results due by the end of April - expect them to announce satisfactory results and perhaps showcasing them in Vegas, it's worth the risk for potential reward. If I'm wrong, that's life, I understand the risk! I just feel the SP will rise to what level I don't know.

Good Luck to you!

OSD, however, it's a big if, but if Dr Marla Dubinsky refinances Trellus Health, brings in a few more revenue deals or even a partnership with a major Pharmaceutical, you will be celebrating with a few Raki's that's for sure!

Regarding QBT, I get your frustration, but now is the time to Top Up, Test results due soon, and I believe this will rise quite sharply!

Good morning,

I believe the Test results will be good (could drop this week or certainly next), and QBT will want to take them to Las Vegas. At this price, it's too much of a risk not to have another punt with QBT hence I'm investing £5k in a minute. Not sure how much the SP will rise, but definitely worth it IMO. Not financial advice.

Just got 1,472,593 shares 👍

GLA

Master82, are you okay? Hopefully the ceasefire is here to stay, and thank goodness for that because unlike you and the other unhinged posters on this board WAR is not good because innocent civilians get killed.

Thank goodness this war seems like it is ending. IMO Brent crude will drop to $50 dollars a barrel by mid May.

Roger, you should be a crime writer! ;)

You can see the 1st and 3rd trade are sells not buys. Why is this information incorrect?

Phimx/Usersteve, just a quick question, if you don't mind answering please.

Assuming in the next two weeks QBT announce the test results are very positive and they're going to showcase the results to potential partners at the Bitcoin conference do you think the SP will spike?

The fact is no one on here knows what's going on behind the scenes. FWIW, at present it doesn't look good, mainly because of the death spiral financing. It's most probably in the top 1% of the riskiest plays on Aim, as the month of May is so close and the likelihood is the money will run out and delisting will come into play. However, if they're indeed sign up further revenue deals and are able to get rid of the death spiral financing (which many Aim companies have managed to do), with alternative funding, this will move so fast. We just don't know. Seen this happen many times before.

This play is one short of putting a bet on a horse race in respect of risk, so anyone that can't afford to lose their whole holding here should not be investing. Only seriously high risk/high rewardinvestors should have shares in this company.

All IMHO not financial advice.

I have reinvested - at this price, it's hard not to.

This stock was born to be traded, and I suspect you can double your money within a few weeks. All IMO - not financial advice.

This was always on the cards. Surely everyone knew the funds were running out.

No mention of how the testing is going? Surely they could've reported how the calculations are coming along before they diluted shareholders once again. I'm started to think it isn't good.

I said a long time ago that I suspected QBT will follow " we're going to mine Bitcoin route"?

Thos company is a joke IMO. I hope some will see the sky through the clouds now and what is going on here.

3/3

Key numbers and disclosures from the RNS

Item Detail

Agreement Renewal of Pfizer licensing for Trellus patient education content in Pfizer’s IBD app

Original start Q2 2024

Financial terms Not disclosed

Monthly cash burn c. $300k (as of March 2026)

Cash runway Expected to extend into May 2026

Loan support From Dr Laurie Keefer, scientific co-founder – amount not disclosed

Recent partner activity Gastro Health MSA; collaboration extension with Johnson & Johnson; continued TrialSet roll-out

Outcomes cited (IBD) Over 90% fewer hospitalisations; over 70% fewer ER visits using Trellus methodology

Positives, risks, and what to watch next

What I like

Blue-chip validation: renewal with Pfizer and continued work with Johnson & Johnson signal credibility with top-tier pharma.

Operating discipline: cash burn at c. $300k per month shows cost control.

Diversified route-to-revenue: licensing, provider agreements, and TrialSet for trials give multiple commercial pathways.

What worries me

Runway is short: “into May 2026” is very near-term, implying urgency on funding.

Limited disclosure: no numbers on the renewal or the loan, making it hard to gauge financial impact.

Execution risk: converting “pipeline opportunities into revenue” remains the key hurdle.

Near-term catalysts to watch

Funding announcement: equity, debt, or strategic – the Board says options are being explored.

Deal flow detail: any update on Gastro Health, Johnson & Johnson, or additional licensing wins.

TrialSet milestones: evidence of uptake across clinical trials would strengthen the growth case.

My take: steady validation, but the funding clock is ticking

This is a neat, confidence-boosting RNS for Trellus. Renewing with Pfizer suggests real engagement with the content and keeps the door open for broader pharma collaborations. Strategically, the company is doing the right things: tighten costs, prove outcomes, and integrate into pharma and provider workflows.

However, the market will focus on runway. Even with the renewal and a co-founder loan, May 2026 is right around the corner. Until we see a concrete funding plan or materially larger contracts, the shares are likely to trade on financing risk as much as on strategic progress.

Bottom line: positive signal on traction, helpful for credibility, and a reminder that execution on revenue and funding remains front and centre.

The RNS set the Pfizer news within a wider push across pharma and clinical trials:

Gastro Health Master Services Agreement – recent, but details not disclosed here.

Extension of collaboration with Johnson & Johnson – a positive signal of stickiness with a tier-one partner, though terms are not provided.

Continued roll-out of Trellus TrialSet – a solution designed to support clinical trials through to commercialisation, leveraging the same resilience science to improve patient engagement and, potentially, trial outcomes.

Put together, Trellus is positioning Trellus Elevate – its whole-person, technology-enhanced condition management platform – as a plug-in for pharma and providers. The company cites outcomes among IBD patients using its methodology of over 90% fewer hospitalisations and over 70% fewer emergency room visits. That is precisely the sort of data that appeals to payers and pharma if it translates into lower costs and better adherence.

Why this matters for investors

Licensing renewals are not just about revenue. They are about validation, product-market fit, and future optionality. If Pfizer’s IBD users are still engaging with Trellus’s content, that supports the stickiness and relevance of the approach. This matters because Trellus is building a B2B model with multiple shots on goal – pharma content licensing, clinical trial support via TrialSet, and provider contracts.

The flip side: the short runway. Extending to “into May 2026” is only a few weeks of visibility. In my view, the renewal is positive for confidence, but the funding clock is still ticking loudly.

Quick primer: the Trellus model in one minute

Trellus Elevate: a digital platform that combines data analytics, education, and expert coaching to help people with complex chronic conditions, currently focused on GI diseases like IBD.

Resilience methodology: a structured, scientifically validated framework to build patients’ coping and self-management skills – aiming for fewer flares, fewer hospital trips, and better adherence.

Value-based angle: supports partners who care about outcomes and costs, from clinical trials to commercial programmes.

Trellus Health has renewed its Licensing Agreement with Pfizer for patient support educational content used in Pfizer’s inflammatory bowel disease (IBD) digital application. It is a tidy validation moment for Trellus’s resilience-based model, and – crucially – part of the reason the company now expects its cash runway to stretch into May 2026.

The recent RNS is light on commercial detail, but the direction of travel is clear: Trellus is leaning into pharma partnerships while tightening costs, and it still needs fresh funding soon.

What exactly did Trellus renew with Pfizer?

The deal is a renewal of a 2024 agreement under which Pfizer licenses Trellus’s patient education content for its IBD app. In simple terms, Trellus provides the content that helps patients understand and manage their condition, built on its “resilience” methodology – a structured approach to supporting the emotional and behavioural side of chronic disease management.

What’s not disclosed: the financial terms, duration of the renewal, expected revenue impact, or user metrics from Pfizer’s app. We do, however, get a strong hint from Trellus’s CEO: the extension “underscores both the continued engagement of their users with our content” and supports the platform’s utility across the pharmaceutical lifecycle.

Trellus has cut its monthly cash burn to an average of c. $300k as of March 2026. With the Pfizer renewal and a loan from scientific co-founder Laurie Keefer, Ph.D., the company expects its runway to extend into May 2026.

Two key points to note:

The size, pricing, and term of the renewal are not disclosed, so it’s unclear how much this contributes to the runway extension.

The loan amount from Dr Keefer is also not disclosed. It is supportive, but it highlights that near-term external financing is still needed.

The Board says it is exploring “a range of potential funding options” to further extend the runway. Translation: expect a financing update sooner rather than later.

Roger, I get your frustration, but most PI's will understand what potentially is going on here with the death spiral financing.

As I said earlier, this is as about high risk, high reward as they get. As many have pointed out there're many positives with this company that could move the SP up at the speed of sound! However, as you and the other pessimists have stated there're many negatives with this company including being placed into administration at anytime. High Risk v High Reward/Lose all your holdings.

IMO, you need to stop with the moaning about this and that, blaming MMs is a pointless excuse/argument because of the level of risk involved investing in this company. No one to blame but yourself I'm afraid. DYOR

It seems to me this level of risk does not fit in with your true attitude to risk vs reward, therefore you shouldn't be invested.

Good Luck 🤞 genuine investors

Roger65, your points are correct, however, what you fail to state is the risk vs reward with this company is as high as possible IMO. For instance I hold 1million shares, that cost approximately £2k, which to me isn't that much and worth a punt. Investing in Trellus, you've to be prepared to lose all your money, but also something may be announced that spikes the SP very quickly (this is high risk, high reward) Who knows? Complaining all the time is pointless.

I suspect most investors are having a punt and understand they can lose all their money hence aren't investing excessive capital.

Roger65, IMO, it's a waste of your time being on these boards. You pop up on different boards whining - surely you've better things to do with your life?